Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSMRF9)

Drug Name

N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide Drug Info

Synonyms

CHEMBL198563; N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[2]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[2]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[3]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[4]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[2]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9.
2	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
3	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
4	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
5	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.